LG Chem Enters Phase 1 Clinical Trial in the US for Its Fourth Anticancer Pipeline

CUE Biopharma Immuno-Oncology Drug 'CUE-102'
Exclusive Development and Licensing Rights Secured in Asia
Establishing Key Cancer Pipelines Including Lung, Head and Neck, and Gastrointestinal Cancers

[Asia Economy Reporter Lee Gwan-joo] LG Chem is expanding its clinical-stage anticancer pipeline to four and enhancing its competitiveness in new drug development.

LG Chem announced on the 12th that its immuno-oncology development partner, the U.S. company Cue Biopharma, received approval from the U.S. Food and Drug Administration (FDA) for the Phase 1 clinical trial plan of 'CUE-102.'

With this clinical approval, Cue Biopharma will evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, and preliminary efficacy of the drug in patients with WT-1 (Wilms tumor gene) positive gastric cancer, pancreatic cancer, ovarian cancer, and colorectal cancer.

CUE-102 is an immuno-oncology agent that selectively recognizes WT-1 positive tumors, directly proliferates T cells (immune cells) that find and eliminate these tumors within the body, and enhances their combat ability. It differs from existing T cell therapies that extract patients' T cells ex vivo, genetically modify and proliferate them, and then reinfuse them into the body.

LG Chem, which holds exclusive development and sales rights in 11 Asian countries including Korea, China, and Japan, plans to design Phase 2 clinical trials in the Asian region based on the partner's Phase 1 clinical data and proceed with direct development.

To strengthen its competitiveness in the oncology field, LG Chem is building a pipeline capable of treating multiple cancers with high medical demand. The Phase 1 clinical trials in the U.S. are underway for the head and neck cancer treatment 'CUE-101' introduced from Cue Biopharma and the solid tumor treatment 'GEN-001' from Korea Genome & Company, while the Phase 1 clinical trial in Europe is ongoing for the non-small cell lung cancer treatment 'PDC* lung' from Belgium and France-based PDC Line Pharma.

Meanwhile, LG Chem has secured a total of 12 clinical-stage new drug pipelines, including four anticancer pipelines.

This content was produced with the assistance of AI translation services.